Walid Mostafa Ahmed

Dr. Walid Mostafa Ahmed


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
Rabab S. HamadRabab S. Hamad
Rabab S. Hamad
WHWaseem Ali Hasan
Waseem Ali Hasan
Sameh SaberSameh Saber
Sameh Saber
Elsayed Abdelhadi Hassan ElmorsyElsayed Abdelhadi Hassan Elmorsy
Elsayed Abdelhadi Hassan Elmorsy
AFAlshaimaa A. Farrag
Alshaimaa A. Farrag
ARAsmaa Ramadan
Asmaa Ramadan

30 November 2023 in Pathophysiology
Verified
Journal Article
Open access
PDF file
MEMagdy Y. Elsaeed
Magdy Y. Elsaeed
Osama Mahmoud MehannaOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
EAEzz-Eldin E. Abd-Allah
Ezz-Eldin E. Abd-Allah
MHMohamed Gaber Hassan
Mohamed Gaber Hassan
WAWalid Mostafa Ahmed
Walid Mostafa Ahmed
MMMohammed Hussein Mohammed
Mohammed Hussein Mohammed
Background: As the impacts of diabetes-induced reproductive damage are now evident in young people, we are now in urgent need to devise new ways to protect and enhance the reproductive health of diabetic people. The present study aimed to evaluate the protective effects of enalapril (an ACE inhibitor) and paricalcitol (a vitamin D analog), individually or in combination, on streptozotocin (STZ)-diabetes-induced testicular dysfunction in rats and to identify the possible mechanisms for this protection. Material and methods: This study was carried out on 50 male Sprague-Dawley rats; 10 normal rats were allocated as a non-diabetic control group. A total of 40 rats developed diabetes after receiving a single dose of STZ; then, the diabetic rats were divided into four groups of equivalent numbers assigned as diabetic control, enalapril-treated, paricalcitol-treated, and combined enalapril-and-paricalcitol-treated groups. The effects of mono and combined therapy with paricalcitol and enalapril on testicular functions, sperm activity, glycemic state oxidative stress, and inflammatory parameters, as well as histopathological examinations, were assessed in comparison with the normal and diabetic control rats. Results: As a result of diabetes induction, epididymal sperm count, sperm motility, serum levels of testosterone, follicle-stimulating hormone (FSH) as well as luteinizing hormone (LH), and the antioxidant enzyme activities, were significantly decreased, while abnormal sperm (%), insulin resistance, nitric oxide (NO), malondialdehyde (MDA), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were significantly increased, along with severe distortion of the testicular structure. Interestingly, treatment with paricalcitol and enalapril, either alone or in combination, significantly improved the sperm parameters, increased antioxidant enzyme activities in addition to serum levels of testosterone, FSH, and LH, reduced insulin resistance, IL-6, and TNF-α levels, and finally ameliorated the diabetes-induced testicular oxidative stress and histopathological damage, with somewhat superior effect for paricalcitol monotherapy and combined therapy with both drugs compared to monotherapy with enalapril alone. Conclusions: Monotherapy with paricalcitol and its combination therapy with enalapril has a somewhat superior effect in improving diabetes-induced testicular dysfunction (most probably as a result of their hypoglycemic, antioxidant, anti-inflammatory, and anti-apoptotic properties) compared with monotherapy with enalapril alone in male rats, recommending a synergistic impact of both drugs.
1

27 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OMOsama Mehanna
Osama Mehanna
BEBasem H. Elesawy
Basem H. Elesawy
AAAhmad Askary
Ahmad Askary
MHMohamed Gaber Mohamed Hassan
Mohamed Gaber Mohamed Hassan
WAWalid Mostafa Ahmed
Walid Mostafa Ahmed
MKMohamed Mansour Khalifa
Mohamed Mansour Khalifa
Background: Diabetic neuropathy (DN) is the most prevalent complication of diabetes, impacting up to 60% of people with diabetes. It is characterized by distal symmetrical loss of sensory function in the lower extremities, presenting with spontaneous excruciating neuropathic pain, hyperalgesia, and allodynia that impairs quality of life. The current work aims to evaluate the neuroprotective potential of naringin (a citrus flavonoid) and examine its ability to improve STZ-induced diabetic neuropathic pain by investigating its hypoglycemic, hypolipidemic, antioxidant, and anti-inflammatory effects. Methods: out of 40 adult male Sprague-Dawley rats, diabetes was induced in 30 rats by a single injection of STZ (45 mg/kg dissolved in citrate buffer). Ten days after induction of diabetes, rats were divided into four groups (10/group): normal control, diabetic control, naringin-treated diabetic rats, and glimepiride-treated diabetic rats as a positive control group. At the end of the experiment, serum and brain tissue samples will be collected then the hypoglycemic, lipid-lowering, antioxidant, and anti-inflammatory effects of naringin will be assessed and compared with that of glimepiride (a standard antidiabetic drug). Hyperalgesia and the effect of the studied drugs on it will also be evaluated by observing pain related behaviors in diabetic rats using hot plate, tail immersion, and mechanical sensitivity (von Frey) tests. Results: Significant increase in the serum levels of glucose, tri-glyceride (TG), total cholesterol (t‐cholesterol), low‐density lipoprotein‐cholesterol (LDL-C), and nitric oxide (NO), with a concomitant decrease in body weight (BW), plasma insulin and high‐density lipoprotein‐cholesterol (HDL-C) were observed in diabetic rats. Also, the brain level of malondialdehyde (MDA) was increased, while that of reduced glutathione (GSH), glutathione peroxidase (Gpx), superoxide dismutase (SOD), and catalase (CAT) were markedly decreased. Furthermore, diabetic rats showed a marked increase in plasma levels of proinflammatory cytokines including interleukin‐6 (IL-6) and tumor necrosis factor‐α (TNF-α). Moreover, hot plate, tail immersion, and von Frey tests revealed hyperalgesia in diabetic rats. Treatment with naringin and glimepiride reduced pain hypersensitivity, restored body weight and nearly normalized the altered biochemical parameters, more significantly with naringin than with glimepiride. Conclusion: These results may highlight the potential effects of naringin as a therapeutic strategy for diabetes and its complications including peripheral neuropathy.

18 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MEMagdy Y. Elsaeed
Magdy Y. Elsaeed
OMOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
EAEzz-Eldin El-Sharkawy Abd-Allah
Ezz-Eldin El-Sharkawy Abd-Allah
MHMohamed G. M. Hassan
Mohamed G. M. Hassan
WAWalid Mostafa Ahmed
Walid Mostafa Ahmed
MMMohammed Hussein Mohammed
Mohammed Hussein Mohammed
Background: As the impacts of diabetes-induced reproductive damage are now evident in young people, we are now in an urgent need to devise new ways to protect and enhance the reproductive health of diabetic people. The purpose of this study was to assess the protective impact of enalapril (an ACE inhibitor) and paricalcitol (a vitamin D analogue) alone and in combination, on streptozotocin (STZ) diabetes-induced testicular dysfunction in rats. Material and methods: This study was carried on 50 male Sprague-Dawley rats; 10 normal rats were allocated as non-diabetic control group. 40 rats developed diabetes after receiving a single dose of STZ, then the diabetic rats were divided into four groups of equivalent number assigned as diabetic control, enalapril treated, paricalcitol treated, in addition to combined enalapril and paricalcitol treated groups. The effects of mono and combined therapy with paricalcitol and enalapril on testicular functions, sperm activity, glycemic state oxidative stress and inflammatory parameters as well as histopathological examination were assessed when compared to the normal and diabetic control rats. Results: As a result of diabetes induction, epididymal sperm count, sperm motility, serum levels of testosterone, follicle stimulating hormone (FSH) as well as luteinizing hormone (LH) and the antioxidant enzyme activities were significantly decreased, while abnormal sperm (%), insulin resistance, nitric oxide (NO), malondialdehyde (MDA), interleukin-6 (IL-6) as well as tumor necrosis factor-α (TNF-α) were significantly increased, along with sever distortion of testicular structure. Interestingly, treatment with paricalcitol and enalapril either alone or in combination significantly improved the sperm parameters, increased antioxidant enzyme activities in addition to serum levels of testosterone, FSH and LH, reduced insulin resistance, IL-6 and TNF-α levels and finally ameliorated the diabetes-induced testicular oxidative stress and histopathological damage with somewhat superior effect for paricalcitol monotherapy and combined therapy with both drugs than monotherapy with enalapril alone. Conclusion: Monotherapy with paricalcitol and its combination therapy with enalapril has a somewhat superior effect in improving the diabetes-induced testicular dysfunction (most probably as a result of their hypoglycemic, antioxidant, anti-inflammatory and anti-apoptotic properties), than monotherapy with enalapril alone in male rats, recommending a synergistic impact of both drugs.
1